The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study.
 
Justin M. Watts
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; Rafael Pharmaceuticals; Reven Pharmaceuticals; Takeda
Research Funding - Bristol-Myers Squibb/Celgene; Immune System Key; Rafael Pharmaceuticals; Reven Pharmaceuticals; Takeda
 
Anthony Hunter
Consulting or Advisory Role - Sierra Oncology
 
Alessandra Iurlo
No Relationships to Disclose
 
Blanca Xicoy
No Relationships to Disclose
 
Francesca Palandri
Honoraria - AOP Orphan Pharmaceuticals; Celgene; CTI; Novartis; Sierra Oncology
Consulting or Advisory Role - AOP Orphan Pharmaceuticals; Celgene; CTI; Novartis; Sierra Oncology
 
Brandi Reeves
Honoraria - Bristol-Myers Squibb; Incyte; PharmaEssentia
 
Alessandro M. Vannucchi
Leadership - AbbVie; AOP Orphan Pharmaceuticals; Blueprint Medicines; GlaxoSmithKline; Incyte; Novartis; Roche
Honoraria - Bristol-Myers Squibb; Incyte; Novartis
Consulting or Advisory Role - AbbVie; AOP Orphan Pharmaceuticals; Blueprint Medicines; GlaxoSmithKline; Incyte; Novartis; Roche
Speakers' Bureau - AOP Orphan Pharmaceuticals; Novartis
 
Prithviraj Bose
Honoraria - AbbVie; Blueprint Medicines; Bristol-Myers Squibb; Cogent Biosciences; CTI; GlaxoSmithKline/Sierra Oncology; Incyte; Kartos Therapeutics; Karyopharm Therapeutics; MorphoSys; Novartis; PharmaEssentia
Research Funding - Astellas Pharma; Blueprint Medicines; Bristol-Myers Squibb; Cogent Biosciences; CTI; Disc Medicine; Incyte; Ionis Pharmaceuticals; Kartos Therapeutics; MorphoSys; NS Pharma; Pfizer; Promedior; Telios
 
Rosa Ayala Diaz
Consulting or Advisory Role - Incyte; Novartis
Speakers' Bureau - Astellas Amgen BioPharama; Bristol-Myers Squibb; Novartis
 
Anna B. Halpern
Consulting or Advisory Role - Abbvie; Agios; Notable labs
Research Funding - Bayer (Inst); disc medicine (Inst); Gilead/Forty Seven (Inst); Imago Pharma (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Karyopharm Therapeutics (Inst)
 
Xuejun Chen
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Francis Seguy
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Feng Zhou
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Fred Zheng
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Pankit Vachhani
Consulting or Advisory Role - Abbvie; Amgen; Blueprint Medicines; CTI BioPharma Corp; Genentech/Roche; Incyte; MorphoSys; Novartis; Pfizer; Stemline Therapeutics
Speakers' Bureau - Incyte
Research Funding - Abbvie (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Blueprint Medicines (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Gilead/Forty Seven (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Seagen (Inst); Takeda (Inst)